A Two-arm, Non-randomised, Open-label Experimental Medicine Study to Compare Immune Responses Between Healthy Volunteers Aged 18-40years Receiving Either an Intranasal Live-attenuated Influenza Vaccine or Viral Challenge With GMP Influenza A/Belgium/4217/2015 (H3N2)
Latest Information Update: 28 Jan 2025
Price :
$35 *
At a glance
- Drugs Influenza virus vaccine live (Primary)
- Indications Influenza virus infections
- Focus Therapeutic Use
- Acronyms GERMINATE
- 28 Jan 2025 New trial record